Beverly Hills Private Wealth LLC Sells 477 Shares of Zoetis Inc. $ZTS

Beverly Hills Private Wealth LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,460 shares of the company’s stock after selling 477 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Zoetis were worth $1,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new stake in Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new stake in Zoetis during the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in shares of Zoetis during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC raised its stake in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.6%

Shares of NYSE ZTS opened at $144.15 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $193.49. The firm’s fifty day moving average is $148.73 and its 200 day moving average is $153.65. The company has a market cap of $63.88 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is presently 34.42%.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.